<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20201024049128N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-12-01</date_registration>
      <primary_sponsor>Karaj University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of the Effectiveness of Intravaginal Misoprostol with Extra-Amniotic Saline Infusion in Labor Induction</public_title>
      <acronym></acronym>
      <scientific_title>A Comparative Study about Maternal and Neonatal Outcomes of Using Extra-Amniotic Saline Infusion and vaginal Misoprostol for Cervical Ripening and Labor Induction in Pregnant Women with Unfavorable Cervix</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-11-10</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>144</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/51808</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Women who consented to participate were randomly selected to receive either Misoprostol or Extra-amniotic Saline Infusion. Group assignment was
determined from a computer-generated table of random
numbers.Some opaque envelopes were used for concealment.</study_design>
      <phase>4</phase>
      <hc_freetext>Unfavorable cervix.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Vaginal Misoprostol. Misoprostol is a prostaglandin E1 analog known to stimulate uterine contractions. In this study 100-microgram tablets were used. In this intervention group, 25 micrograms of misoprostol (1/4 of 100-microgram tablet) was inserted intravaginally in the posterior fornix every 4 hours up to 5 doses. The maximal cervical ripening period until labor induced was 24 hours, regardless of the number of doses received. Intravenous oxytocin was given to the misoprostol group for the following reasons:(1) active labor did not occur after the maximum number of doses of misoprostol had been given, (2) spontaneous rupture of the membranes occurred without anadequate contraction pattern, or (3) dilation was arrested (no change in cervical dilation for &gt;2 hours). Intervention 2: Intervention group: Extra-amniotic saline infusion. Saline is a type of isotonic solution and a mixture of salt and water. The concentration is 9 grams per litre (0.9% saline) . In this group, women underwent a speculum examination. After preparation of the cervix with Betadine solution, an18-gauge Foley catheter balloon was inserted to above the internal cervical os. The balloon was inflated to 30 milliliters with sterile normal saline solution, the Foley catheter was taped to the inner aspect of the subject’s thigh without any traction. A normal saline solution infusion of 30 mL per hour through the central lumen of the Foley catheter was initiated concurrently with intravenous oxytocin. Oxytocin infusion was started at a rate of 1.0 milliunits per minutes and was increased in nine stepwise increments to a maximum of 22.0 milliunits per minutes at 30-minute intervals as needed to achieve an adequate contraction pattern. The Foley catheter was removed for the following reasons: (1) 12 hours had elapsed since the initial placement (2) spontaneous rupture of membranes occurred, (3) evidence of fetal distress was noted, (4) the catheter was expelled spontaneously, or (5) the patient could no longer tolerate the procedure.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is No more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Bita Badehnoosh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Kamali hospital; Kamali alley; Shohada square; Shahid Beheshti street</address>
        <city>Karaj</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3149779453</zip>
        <telephone>+98 26 3222 2021</telephone>
        <email>b_badehnoosh@yahoo.com</email>
        <affiliation>Karaj University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Bita badehnoosh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Kamali hospital; Kamali alley; Shohada square; Shahid Beheshti street</address>
        <city>Karaj</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3149779453</zip>
        <telephone>+98 26 3222 2021</telephone>
        <email>b_badehnoosh@yahoo.com</email>
        <affiliation>Karaj University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Singleton gestation
Alive fetus
Cephalic presentation
Intact membranes
Unfavorable cervix (Bishopscore ≤6)
Reassuring fetal heart rate
Gestational age≥28</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Non-cephalic presentation
Adequate uterine contractions (3 contractions Lasting for 30sec/10 min)
Ruptured membranes
Cephalopelvic disproportion
Multiple pregnancy
Polyhydramnios
Estimated fetal weight ≥4000g or ≤1800g
Placental abruption, Placenta previa
Unexplained vaginal bleeding
Prior lower segment cesarean section/Scarred uterus
Non-reassuring fetal status
Clinically detected vaginal infections(exp:genital herpes) or chorioamnionitis
Latex or Prostaglandins allergy or any contraindications receiving Prostaglandins, including a history of asthma, glaucoma, or cardiovascular disease
Intrauterine fetal death
Renal or hepatic failure</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Devices</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Vaginal Misoprostol. Misoprostol is a prostaglandin E1 analog known to stimulate uterine contractions. In this study 100-microgram tablets were used. In this intervention group, 25 micrograms of misoprostol (1/4 of 100-microgram tablet) was inserted intravaginally in the posterior fornix every 4 hours up to 5 doses. The maximal cervical ripening period until labor induced was 24 hours, regardless of the number of doses received. Intravenous oxytocin was given to the misoprostol group for the following reasons:(1) active labor did not occur after the maximum number of doses of misoprostol had been given, (2) spontaneous rupture of the membranes occurred without anadequate contraction pattern, or (3) dilation was arrested (no change in cervical dilation for &gt;2 hours)</i_keyword>
      <i_keyword>Intervention group: Extra-amniotic saline infusion. Saline is a type of isotonic solution and a mixture of salt and water. The concentration is 9 grams per litre (0.9% saline) . In this group, women underwent a speculum examination. After preparation of the cervix with Betadine solution, an18-gauge Foley catheter balloon was inserted to above the internal cervical os. The balloon was inflated to 30 milliliters with sterile normal saline solution, the Foley catheter was taped to the inner aspect of the subject’s thigh without any traction. A normal saline solution infusion of 30 mL per hour through the central lumen of the Foley catheter was initiated concurrently with intravenous oxytocin. Oxytocin infusion was started at a rate of 1.0 milliunits per minutes and was increased in nine stepwise increments to a maximum of 22.0 milliunits per minutes at 30-minute intervals as needed to achieve an adequate contraction pattern. The Foley catheter was removed for the following reasons: (1) 12 hours had elapsed since the initial placement (2) spontaneous rupture of membranes occurred, (3) evidence of fetal distress was noted, (4) the catheter was expelled spontaneously, or (5) the patient could no longer tolerate the procedure.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The mean time interval from start of induction to delivery. Timepoint: Time of birth. Method of measurement: Clock.</prim_outcome>
      <prim_outcome>Duration of latent phase. Timepoint: At the end of latent phase. Method of measurement: Clock.</prim_outcome>
      <prim_outcome>Duration of active phase. Timepoint: At the end of active phase. Method of measurement: clock.</prim_outcome>
      <prim_outcome>Rate of delivery within 12 hours. Timepoint: At the end of study. Method of measurement: Patient's file.</prim_outcome>
      <prim_outcome>Rate of delivery within 24 hours. Timepoint: At the end of study. Method of measurement: Patient's file.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Cesarean rate. Timepoint: At the end of study. Method of measurement: Patient's file.</sec_outcome>
      <sec_outcome>Incidence of tachysystole. Timepoint: Continuously. Method of measurement: Cardiotocography.</sec_outcome>
      <sec_outcome>Incidence of  hypertonus. Timepoint: Continuously. Method of measurement: Cardiotocography.</sec_outcome>
      <sec_outcome>Apgar score. Timepoint: 1 minute and 5 minutes after birth. Method of measurement: Examination of the newborn.</sec_outcome>
      <sec_outcome>Incidence of meconium passage. Timepoint: At birth. Method of measurement: Examination of the newborn.</sec_outcome>
      <sec_outcome>Incidence of chorioamnionitis. Timepoint: Every 3 hours. Method of measurement: Physical examination.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Karaj University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-10-10</approval_date>
        <contact_name>Ethics committee of Alborz University of Medical Sciences</contact_name>
        <contact_address>Ethics committee unit; Vice Chancellor for Research; No.20; Saffarian alley; 45 Metri Golshahr street Karaj Alborz Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
